Skip to main content
Premium Trial:

Request an Annual Quote

BioSkryb, St. Jude Expand Licensing Deal for Dx Applications of Single-Cell Tech

NEW YORK – Single-cell assay developer BioSkryb announced Monday an exclusive agreement to license technology from St. Jude Children's Research Hospital that it plans to use in a diagnostic test to detect and define populations of cancer cells during treatment.

The deal builds on a previous exclusive licensing agreement for research-based applications of primary template-directed amplification technology. BioSkryb will initially focus on hematologic cancers, followed by the development of similar solutions for solid tumors, the partners said. Financial and other terms of the deal were not disclosed.

BioSkryb's SkrybAmp technology offers whole-genome amplification of single-cells, with the ability to enrich for and capture subsets. The Durham, North Carolina-based firm was cofounded by Stanford University Medical School professor Charles Gawad, who developed PTA while working at St. Jude.

"With this expanded licensing agreement, we hope to use this technology developed by scientists at St. Jude to generate diagnostic solutions that provide real insights to improve cancer treatments," BioSkryb CEO and Cofounder Jay West said in a statement.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.